Skip to main content


Anna Ljung, CEO , M.Sc. Econ.

Born 1980. Has worked for the company since 2006. Anna Ljung has served as the CFO of Athera Biotechnologies AB and Lipopetide AB, and worked as an independent consultant in the field of technology licensing. She is also a board member of Saniona AB.
Shareholding: 13 994 shares, 10 379 performance share units and 55 000 employee stock options (55 000 shares may be subscribed to, based on the employee stock options).


Torbjörn Wärnheim, Deputy CEO & Senior Vice President R&D

Born 1958. Has worked for the company since 2013. Prior to his position with Moberg, Torbjörn Wärnheim was Vice President R&D at Fresenius Kabi. In addition to this he has held senior level positions at ACO HUD and Pharmacia & Upjohn among others. Torbjörn Wärnheim has a broad experience of pharmaceutical development of Rx- and OTC-products, and is associate professor at Royal Institute of Technology (KTH), Stockholm, with a research background within surface chemistry and physical chemistry of lipids.

Shareholding: 6 635 aktier, 11 113 performance share units och 19 000 employee stock options (19 000 shares may be subscribed to, based on the employee stock options).

Annica Magnusson, Senior Director of Regulatory Affairs

Born in 1963. Has worked for the company since 2013. Annica Magnusson is a pharmacist with more than 20 years of experience in international work within the pharmaceutical industry and Regulatory Affairs at AstraZeneca. Annica Mangusson has worked with the development and registration of pharmaceuticals, vaccines and medical devices in the EU, USA, Japan with several markets.

Shareholding: 4 030 shares and 7 805 performance share units and 28 500 employee stock options (28 500 shares may be subscribed based on employee stock options).


Mark Beveridge, Vice President Finance

Born 1978. B. Com, GradDipCA. Active in the company since 2015. Mark Beveridge has more than 15 years of experience as an advisor in accounting, insurance and auditing, primarily from Crowe Horwath and Visma Services. Mark has also worked as an independent consultant within financial control, transaction consultancy and implementation of business systems.

Shareholding: 26 500 shares and 19 683 performance share units and 4 273 employee stock options (4 273 shares may be subscribed based on employee stock options).


Cindy Wong, Chief Medical Officer

Born 1959. Dr Cindy Wong takes up the position at Moberg Pharma in late 2020. She brings extensive international experience in clinical development and registration of new products in a number of treatment areas  including Dermatology. She has held positions as Vice President and Head of Global Clinical Development at Merz Pharmaceuticals and CMO at Q-Med/Galderma, as well as senior positions at regulatory authorities in both Sweden and Australia. Dr Wong is board certified in internal medicine and clinical immunology. She is a medical graduate from the University of Adelaide and has completed postgraduate training in Internal Medicine, Clinical Immunology and Immunopathology.

Shareholding: 0 shares, 0 performance share units och 0 employee stock option.

Current shareholding is not automatically updated for the moment. Insiders no longer have obligation to report there shareholding. According to the regulatory requirements, the data shall be updated once a year.